Infection and Inflammation: Catalysts of Pulmonary Morbidity in Bronchopulmonary Dysplasia

  • Phillip S. Wozniak
  • Mohannad Moallem
  • Pablo J. SánchezEmail author
Part of the Respiratory Medicine book series (RM)


Bronchopulmonary dysplasia (BPD) is the most frequent pulmonary morbidity among survivors of prematurity. While the precise cause remains unknown, both antenatal factors, and specifically chorioamnionitis, as well as bacterial sepsis, cytomegalovirus infection, and respiratory viral infections have been associated with the pathogenesis of BPD. This chapter will focus on the impact that inflammation and infection have on the development of BPD in preterm infants and its long-term pulmonary morbidities. Knowledge of the respiratory tract microbiome and virome and their role in the development of BPD constitutes a major knowledge gap in our continuing efforts to decrease the incidence of BPD and its consequences.


Preterm Infant Respiratory Virus Respiratory Viral Infection Histological Chorioamnionitis Antenatal Inflammation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Despite improvements in the care of preterm infants with gentler ventilation techniques, antenatal glucocorticoid therapy, and surfactant treatment, bronchopulmonary dysplasia (BPD) remains a major public health problem worldwide. BPD, as defined by the need for supplemental oxygen at 36 weeks’ postmenstrual age [1, 2, 3], is the most frequent pulmonary morbidity among survivors of prematurity—a chronic lung condition that affects more than 10,000 premature infants in the United States alone each year [4, 5]. Before the surfactant era, BPD was primarily a structural injury of the preterm lung characterized by decreased alveolarization and surface area, alternating atelectasis with hyperinflation, pulmonary lesions, and fibrosis [6]. Today, BPD represents a developmental arrest of the preterm lung with interruption of the pulmonary septation, alveolarization, and vascularization during the saccular and alveolar stages of lung development [7].The result is a lung with fewer, larger alveoli and a corresponding decrease in surface area available for gas exchange.

The 2014 National Institutes of Health Heart, Lung, and Blood Institute workshop on prevention of BPD identified six possible causative factors associated with BPD: structurally and biochemically immature lungs, hyperoxia and oxidant injury, mechanical injury associated with positive pressure respiratory support, poor respiratory drive and apnea, poor nutrition, and importantly, infection and inflammation [5]. Any or all of these factors, possibly in concert with genetic predisposition or epigenetic factors, could contribute to its occurrence, even though recent genome-wide association studies (GWAS) failed to identify any specific loci associated with moderate to severe BPD [8, 9]. Clearly, the pathophysiology of BPD is complex and likely multifactorial, but a central role for pulmonary inflammation seems critical to its development.

Antenatal Infection and Inflammation

There is a substantial body of literature associating “chorioamnionitis” with the development of BPD, with recent meta-analyses demonstrating odds ratios of 3.0 and 2.2 for the occurrence of BPD at 28 days of age and 36 weeks postmenstrual age, respectively [10]. How chorioamnionitis contributes to the development of BPD, however, remains a topic of ongoing debate.

Chorioamnionitis is diagnosed often as symptomatic maternal disease with intrapartum fever in association with clinical and laboratory signs of infection or inflammation, but more appropriately, by histopathology [11]. The so-called histological chorioamnionitis can be acute or chronic based on neutrophilic or lymphocytic infiltration of the fetal membranes, respectively. Both neutrophils and lymphocytes may be of either maternal or fetal origins [12]. Unlike acute cases, chronic chorioamnionitis has both cellular (innate) and humoral (adaptive) immune responses, which could indicate maternal antibody-mediated antifetal rejection that has been associated with preterm birth [13]. The suggestion by Goldenberg et al. [14] that intrauterine infection and/or inflammation accounts for up to 90 % of preterm births before 28 weeks’ gestation lends credence to the theory that predisposition of preterm infants to BPD may occur in utero.

Ureaplasma parvum and Ureaplasma urealyticum, both genital mycoplasmas, are the most common bacteria isolated from placentas with histological chorioamnionitis as well as from amniotic fluid [15, 16, 17]. These organisms are typically of low virulence, and thus capable of producing a chronic infection of the uterine cavity and fetal compartment [14, 18]. In fact, neonatal colonization with Ureaplasma spp. has been associated with chorioamnionitis [19].

Prospective cohort studies have associated Ureaplasma colonization with the development of BPD [20, 21]. Respiratory tract colonization with Ureaplasma spp. occurs in 28–33 % of infants with birth weight <1500 g, and among those < 26 weeks’ gestation, as many as 65 % of infants are culture-positive or polymerase chain reaction (PCR)-positive for Ureaplasma spp. at least once in the first month of age [22]. Ureaplasma colonization increases with decreasing gestational age, a finding that correlates with the risk of developing BPD [23].

Several mechanisms for the association of Ureaplasma colonization of preterm infants and BPD have been proposed. The ability of Ureaplasma spp . to hydrolyze urea as their sole source of energy results in the generation of ammonium ions that interact with lung water to form ammonium hydroxide and potentially result in mucosal/epithelial injury and inflammation [24]. However, the major virulence factor that has been identified experimentally is the Ureaplasma multiple banded antigen (MBA), a surface-exposed lipoprotein [22]. Ureaplasma spp . have been shown to evade the host immune response by varying the size of MBA and mba gene [22, 24]. Both MBA and mba gene size variants have been detected in infected sheep amniotic fluid and fetal lung, and the size variation also has correlated with the severity of chorioamnion inflammation.

Clearance of Ureaplasma species from the lung also appears to be dependent on local host immune response mediators, such as surfactant protein-A (SPA) [15]. Okugbule-Wonodi et al. [25] demonstrated that SPA increased phagocytosis and killing of Ureaplasma spp. by macrophages. In a mouse model, SPA-deficient mice showed delayed clearance of Ureaplasma from the lungs, increased inflammatory cells, and increased proinflammatory cytokine expression [26]. These findings are particularly relevant for preterm infants who lack robust immune responses and endogenous SPA production in the first 48 h of age.

Does Chorioamnionitis Cause BPD?

Intra-amniotic inflammation (IAI) secondary to histological chorioamnionitis can result in premature maturation of the fetal lung that is mediated by such proinflammatory cytokines as interleukin (IL)-1α, IL-1β, IL-6, IL-8, and tumor necrosis factor (TNF)-α. These can act directly on fetal lung cells, including the Type II alveolar cells that produce surfactant [27, 28]. In rabbits, Bry et al. [29] demonstrated that IL-1α enhanced messenger RNA transcription of both surfactant proteins and lipids resulted in improved lung compliance [12, 29]. Although the proinflammatory cytokines protected against the development of respiratory distress syndrome (RDS), the fetal inflammation has been associated subsequently with increased incidence of BPD [12, 27, 30, 31].

While the signaling pathways responsible for lung development have been well characterized, the effects of chorioamnionitis and/or antenatal inflammation on those pathways have not [32, 33]. Bacterial antigens such as lipopolysaccharide can cause altered distribution of elastin, the mesenchymal structural protein responsible for proper septation of the lung [12, 34, 35]. Intra-amniotic inflammation also can cause dysregulation of critical growth factors necessary for lung development. Fibroblast growth factor (FGF)-10 expression is inhibited by nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), the major proinflammatory signaling pathway stimulated by IL-1 and TNF-α [36, 37]. FGF-10 plays a key role in lung branching morphogenesis, remodeling, repair, and regeneration [12, 38]. Inhibition or dysregulation of these key functions as a consequence of histological chorioamnionitis or inflammation has resulted in a lung condition in animals that is similar to BPD in humans [35].

The effects of antenatal inflammation are not limited to the developing airway. The developing pulmonary vasculature also is susceptible to adverse remodeling due to antenatal inflammation, limiting the capacity for gas exchange in the preterm lung. Antenatal inflammation can inhibit vascular endothelial growth factor (VEGF), angiopoietin-1, transforming growth factor-β (TGF-β), endoglin, connective tissue growth factor (CTGF), endothelial nitric oxide synthase (eNOS), platelet endothelial cell adhesion molecule-1 (PECAM-1), and VEGF-receptor 2 (VEGF-R2) [12, 39, 40]. In addition, antenatal inflammation can cause smooth muscle hypertrophy in the pulmonary vasculature, predisposing to pulmonary hypertension that is a major complication of BPD [12, 39]. VEGF is responsible for the regulation of eNOS, which plays a crucial role in the regulation of pulmonary vascular tone and modulation of pulmonary vascular development. PECAM-1 and VEGF-R2 are essential for proper development of pulmonary endothelial cells [39].

It seems clear that antenatal inflammation alone has the potential to cause both impaired alveolarization and reduced development of the pulmonary vasculature leading to the development of BPD in some at-risk preterm infants, even in the absence of mechanical ventilation [39, 41]. However, other indirect mechanisms linking chorioamnionitis and/or inflammation to BPD may be involved.

Does Chorioamnionitis Make the Lung Susceptible to BPD?

Exposure of the preterm fetus to chorioamnionitis may result in a systemic fetal inflammatory response syndrome (FIRS) with activation of the innate immune system [42, 43] and manifested by histological chorioamnionitis with funisitis and increased umbilical cord blood concentrations of proinflammatory cytokines [42]. Such infants have a decreased clinical response to exogenous surfactant, more frequent use of exogenous surfactant, increased need for mechanical ventilation, longer time to extubation, longer supplemental oxygen use, and more frequently develop BPD [43, 44, 45].

Mechanical factors also contribute to the development of BPD. Hillman et al. [46] showed that as few as six breaths at high tidal volumes were sufficient to eliminate the surfactant response in fetal sheep. Furthermore, 15 min of ventilation at escalating tidal volumes has been associated with a substantial inflammatory response in the preterm lung that is characterized by production of multiple classes of cytokines and other proinflammatory markers, increased mRNA for IL-1β and IL-6, increased inflammatory cell infiltrates, increased alveolar wall thickening, and decreased alveolar expansion, with a concomitant delayed or deficient release of the anti-inflammatory cytokine, IL-10 [47, 48]. Of note, stretch injury overlapped consistently with the maturational effects induced by chorioamnionitis and prolonged LPS exposure in utero [46].

Supplemental oxygen supplied to the preterm infant, whether by mechanical ventilation or other support measures, such as continuous positive airway pressure (CPAP) or nasal cannula, also has injurious effects on the preterm lung by inducing an inflammatory response [45]. This inflammation stimulates the activity of VEGF and causes breakdown of the alveolar–capillary barrier, vascular leakage, introduction of proinflammatory mediators, pulmonary edema, and, ultimately, endothelial apoptosis [45, 49]. An animal study of hyperoxia-induced BPD in preterm rabbits identified 2217 dysregulated pathophysiological pathways affecting inflammation, vascular development, and reactive oxygen species (ROS) metabolism [50]. Because antioxidant defense do not develop until much later in gestation, preterm infants receiving high concentrations of oxygen are particularly susceptible to ROS-mediated injury [51, 52].

Antenatal inflammation due to chorioamnionitis also has been linked to the development of BPD through immune tolerance due to the preterm lung’s structural immaturity and the preterm infant’s immature immune system [12, 53]. Several in vitro and animal studies have indicated that intrauterine endotoxin/LPS exposure can downregulate immune responses akin to tolerance [54, 55, 56, 57]. LPS-induced immune paralysis may be caused by reduced expression of major histocompatibility complex II (MHC) antigen on fetal blood monocytes and increased expression of the immunosuppressive cytokines, IL-10 and TGF-β [12, 57].

Repeated exposure to LPS in Ureaplasma-infected fetal sheep induces both endotoxin tolerance and tolerance of other toll-like receptor (TLR) agonists [55]. Since TLRs are major activators of the immune system, cross-tolerance of toll-like agonists may enhance immune suppression in the preterm infant and increase the vulnerability to a “second hit”—sepsis, ventilator-mediated injury, or hyperoxia [12, 55]. On the other hand, Kramer and Jobe [56] hypothesized that this immunosuppressive fetal response may be an advantageous adaptation to chronic exposure to chorioamnionitis that prevents more serious inflammation-mediated lung injury. Indeed, Kallapur et al. [58] lent weight to this theory when they showed that chronic exposure to intra-amniotic endotoxin did not lead to progressive lung injury and extensive structural abnormalities in fetal sheep, but only to mild, persistent inflammation. However, chorioamnionitis leading to prolonged immune dysfunction may subsequently increase susceptibility to postnatal infections.

Bacterial Sepsis and BPD

Early-onset sepsis (≤72 h after birth) has been shown to initiate an inflammatory cascade in preterm infants similar to that seen with exposure to histological chorioamnionitis. Similarly, late-onset sepsis (LOS; >72 h of age) causes both proinflammatory and profibrotic responses in the preterm lung, increasing its susceptibility to BPD [45, 59, 60].

In a retrospective study of 7509 infants born at <32 weeks’ gestation in 29 neonatal intensive care units (NICUs) of the Canadian Neonatal Network from 2010 to 2011, Shah et al. [59] identified 1104 (15 %) infants with LOS, defined as a positive blood and/or cerebrospinal fluid bacterial culture. Of these 1104 infected infants, 909 (82 %) had Gram-positive and 195 (18 %) had Gram-negative infections. As compared with no infection, the odds ratio (OR) of mortality/BPD was higher in infants who had Gram-negative (OR, 2.79; 95 % confidence interval [CI], 1.96–3.97) and Gram-positive (OR, 1.44; 95 % CI, 1.21–1.71) sepsis. Infants with Gram-negative sepsis were significantly more likely to have been born to mothers with chorioamnionitis than uninfected infants (p = 0.004) or those with Gram-positive infections (p = 0.04). This study supports the contention that the proinflammatory cascade that occurs with LOS can exacerbate preexisting inflammatory conditions associated with chorioamnionitis exposure or initiate an inflammatory and fibrotic response that results in BPD [45, 59, 61, 62]. Prevention of postnatal sepsis must remain a high priority for prevention of BPD.

Cytomegalovirus Infection and BPD

Congenital cytomegalovirus (CMV) infection is the most common congenital viral infection in developed nations, occurring in approximately 0.1–2.0 % of all live births [63, 64]. CMV is a Betaherpesvirinae virus that infects human leukocytes, and transmission to the infant occurs transplacentally following primary maternal infection, reactivation of latent maternal infection, or maternal reinfection with a different viral strain [64]. In addition, infants can acquire the virus during birth from exposure to infected vaginal and cervical secretions, or postnatally by either blood transfusion or, more commonly, ingestion of human milk from a CMV-seropositive mother [65, 66]. Intrapartum and postnatal acquisition of CMV, defined as detection of CMV in body fluids at ≥21 days of age, and to a lesser extent congenital infection, can result in pneumonitis and increased likelihood for development of BPD in preterm infants [64, 67].

In 1976, Whitley et al. [68] first noted the association of perinatally acquired CMV infection with protracted pneumonitis in two infants with lower respiratory tract obstruction at 1 month of age [68]. Virological, serological, immunological, and electron microscopic studies indicated that CMV was a major causative factor. Subsequently, case reports associated multicystic lung disease, fibrosis, and pulmonary hypertension with postnatal CMV infection [1, 69, 70, 71].

Two recent studies provide new evidence for an association between postnatal acquisition of CMV and BPD. Mukhopadhyay et al. [72] conducted a retrospective review of 145 very low birth weight (VLBW, ≤1500 g) infants who were tested for CMV infection while in the NICU at Brigham and Women’s Hospital, Boston from 1999 to 2013. Of the 145 infants, 27 (19 %) had postnatal detection of CMV defined as diagnosis at ≥21 days of age; all had birth weight <1250 g and were born at <32 weeks’ gestation. Sixteen (59 %) infants presented with acute respiratory decompensation, and importantly, CMV-infected infants had significantly more exposure to mechanical ventilation (p = 0.03) and a higher incidence of BPD (OR 4.0; 95 % CI, 1.3–12.4; p =0.02). The authors suggested that postnatal symptomatic CMV infection, like late-onset bacterial sepsis, may predispose to development of BPD by a combination of direct pathogen effects on the lung, inflammation, and/or increased exposure to mechanical ventilation and supplemental oxygen.

Similarly, in a propensity-matched retrospective cohort study of 101,111 VLBW infants at 348 NICUs managed by the Pediatrix Medical Group from 1997 to 2012, 328 (0.3 %) infants had a diagnosis or detection of CMV at ≥21 days of age [73]. Postnatal CMV infection was associated with an increased risk for death or BPD at 36 weeks’ postmenstrual age (risk ratio, 1.21; 95 % CI, 1.10–1.32) and BPD (risk ratio, 1.33; 95 % CI, 1.19–1.50). Changes in cardiorespiratory status associated with postnatal CMV infection included a new requirement for vasopressor medications (9 %; n = 29), intubation for mechanical ventilation (15 %; n = 49), a new oxygen requirement (28 %; n = 91), and death (1.2 %; n = 4).

Given the association of postnatal acquisition of CMV with BPD, the key challenge remains development of preventative measures against CMV acquisition in extremely low gestational age infants. Transmission of CMV by blood transfusion to preterm infants has been virtually eliminated by the use of CMV antibody-negative donors, freezing red blood cells in glycerol before administration, or leukoreduction. Ingestion of human milk now is the primary means by which preterm infants acquire CMV postnatally [74]. While pasteurization of human milk inactivates CMV, it also may reduce its known cognitive, immunological, and nutritional benefits. Freezing milk at −20 °C decreases CMV viral titers, but does prevent transmission [75, 76].

Respiratory Viral Infection and BPD

The occurrence of respiratory viral infections in preterm infants in the NICU has been documented in a prospective surveillance study performed in two NICUs in Syracuse, NY during a 1-year period [77]. Fifty preterm infants <33 weeks’ gestation who were in the NICU since birth underwent nasopharyngeal swab testing for detection of respiratory viruses (influenza A/B; respiratory syncytial virus [RSV] A/B; parainfluenza [PIV] 1–4; coronavirus, human rhinovirus/enterovirus [hRV]; adenovirus; human metapneumovirus [HMPV]) by multiplex PCR testing twice weekly within 3 days of birth and up to the time of discharge. Fifty two percent (26/50) of infants tested positive for a respiratory virus at least once during the NICU stay. Of 708 specimens obtained, the following viruses were detected: PIV-3, 13; hMPV, 9; RSV-B, 8; RSV-A, 7; PIV-2, 7; hRV, 7; and influenza B, 4. Of note, 18 samples (28 % of the positive swabs) included more than one virus, similar to studies performed in older infants with bronchiolitis where viral codetection is relatively common. Fourteen infants had sequentially positive specimens for the same virus over 3 to 13 days, suggesting that these were true positive results. Compared to infants who did not have a respiratory viral pathogen detected, virus-positive infants had significantly longer length of stay (70 d vs. 35 d, p = 0.002), need for intubation (65 % vs. 29 %, p = 0.01), duration of intubation (19 vs. 5 d, p = 0.03), duration of oxygen requirement (51 vs. 13 d, p = 0.002), more episodes of desaturation (p < 0.0001), and clinical deterioration episodes (p = 0.0001), and importantly, BPD (46 % vs. 21 %, p = 0.05).

In a single-site prospective study performed in a German NICU from 8/2010–3/2014, Kidszun et al. [78] performed respiratory viral multiplex PCR testing on 88 infants (median gestational age, 27 weeks; median birth weight, 852 g) who underwent 137 evaluations for late-onset sepsis. A respiratory virus was detected in the nasopharynx of six (7 %) infants (2, RSV; 4, picornavirus). Similarly, Ronchi et al. [79] conducted a 1-year study (1/15/12–1/31/13) for the detection of respiratory viruses by multiplex PCR testing in infants evaluated for possible sepsis and in whom intravenous antibiotic therapy was initiated. During the 13-month study, 100 infants (mean gestational age, 31 weeks; mean birth weight, 1698 g) had 135 sepsis evaluations, and 8 infants (8 %), or 6 % (n = 8) of sepsis evaluations, had a respiratory virus detected from nasopharyngeal swabs. These included hRV(n = 4), coronaviruses (1, HKU-1; 1, OC43), and PIV-3 (n = 2). These studies suggest that respiratory viral infections are under-recognized in premature infants in the NICU; yet, they are associated with acute morbidity. Their contribution to long-term respiratory and neurodevelopmental outcomes, however, remains unknown.

It is likely that respiratory viral infections can exacerbate the underlying lung abnormalities of infants with BPD and result in impairment of lung function through early childhood and possibly adolescence. Longitudinal studies of mice who received supplemental oxygen have found a lifelong increased susceptibility to infection with respiratory viruses, and in particular, influenza A virus, compared to preterm controls exposed only to room air [80, 81, 82]. Higher oxygen concentrations led to a dose-dependent inflammatory response to influenza A exposure [45, 52, 83], with enhanced recruitment of macrophages, neutrophils, and lymphocytes, as well as increased alveolar fibrosis, increased monocyte chemoattractant protein (MCP-1), and greater mortality [80]. O’Reilly et al. [80] demonstrated that alveolar type II cells that are responsible for surfactant production can express viral receptors on their surface, with surfactant protein-deficient mice having decreased viral clearance. Pulmonary outcomes of preterm infants infected with a respiratory virus early in life—and especially with RSV, hRV, PIV, and hMPV—bear striking resemblance to outcomes of very premature infants with BPD [84, 85]. Both BPD and early respiratory infection with RSV have been associated with recurrent wheeze and lung function abnormalities that persist to school age [64, 86]. In addition, viral lower respiratory tract infections (LRTIs) may be a marker for preexisting abnormal lung function in neonates [64, 87]. Infants with BPD have substantially more rehospitalizations due to RSV and hRV infection than age-matched controls without BPD [88, 89].

Similar to BPD, RSV also has been shown to cause persistently diminished lung function among preterm infants and increased wheezing throughout childhood [90, 91, 92, 93, 94]. Preterm infants hospitalized with RSV infection are significantly more likely to require supplemental oxygen and mechanical ventilation, exposing them to additional pulmonary injury [88]. In 2015, the SPRING study demonstrated that among children born at 32–35 weeks’ gestation, RSV hospitalization was associated with increased wheezing through 6 years of age, as well as increased utilization of health care resources and decreased self-reported quality of life [95].

The humanized monoclonal antibody, palivizumab, has been shown to significantly reduce RSV hospitalizations in infants and children at high risk for severe RSV infection [96]. Simoes et al. [97] conducted a cohort study of 421 preterm infants who had received palivizumab and were not hospitalized for RSV (n = 191) or who never received palivizumab (n = 230; 76 hospitalized for RSV). Infants who received palivizumab had significantly less parent-documented and physician-diagnosed recurrent wheezing. Similarly, the Dutch RSV Neonatal Network conducted a multicenter, double-blind, placebo-controlled trial of palivizumab prophylaxis in 429 otherwise healthy preterm infants of 33 to 35 weeks’ gestation and demonstrated that palivizumab prophylaxis significantly reduced wheezing days during the first year of age [98]. These studies continue to implicate RSV infection as an important mechanism of recurrent wheeze during the first year of life in preterm infants.

Future Directions

As the direction of causality between infection, inflammation, and BPD remains unanswered, research is needed to better elucidate their interaction and contribution to long-term pulmonary morbidity in preterm infants, with the ultimate goal of developing and implementing novel therapies and interventions. Nonetheless, a central role for pulmonary inflammation seems key, and the factors that contribute to its evolution need to be explored.

Early and prolonged antibiotic therapy in preterm infants has been associated with BPD [99], suggesting an important role of the airway microbiome as a mediator of the inflammatory process [100]. Recently, Lal et al. [101] reported temporal dysbiotic changes in the airway microbiome from birth to the development of BPD in preterm infants. They noted decreased Lactobacillus spp . in endotracheal aspirates of preterm infants who developed BPD and infants born to mothers with chorioamnionitis. How the airway microbiome is established, and the possible factors such as chorioamnionitis, antibiotic use, and postnatal infection that potentially contribute to its dysregulation need further exploration [102].

The human virome, or the viral component of the human microbiome, represents the collection of all viruses that are found in or on humans, including viruses that cause acute, persistent, or latent infection, and viruses that integrate into the human genome, such as endogenous retroviruses [103]. The human virome includes both eukaryotic and prokaryotic viruses (bacteriophages), the latter of which can infect the broad array of bacteria that inhabit the body and influence bacterial population structure or virulence. Its impact on human health has received less attention than that of the bacterial microbiome, even though it is likely to be equally important in homeostasis and disease. The potential importance of the human virome in the development of BPD is not known, and our current lack of understanding of its ontogeny in preterm infants constitutes a major knowledge gap in our continuing efforts to decrease the incidence of BPD and its consequences.

Finally, genome-wide transcriptional profiles of the infant’s inflammatory response to conditions associated with prematurity could provide new key evidence about the pathogenesis of BPD [104]. Analysis of the infant’s transcriptome also could be used to support the clinical significance of detecting bacterial or viral sequences in clinical specimens by detecting expression of immune/inflammatory genes that may contribute to the development of BPD [105]. Importantly, such technology could aid in the identification and subsequent validation of candidate biosignatures and biomarkers for BPD in preterm infants with bacterial and respiratory viral infections.


  1. 1.
    Nijman J, de Vries LS, Koopman-Esseboom C, Uiterwaal CS, van Loon AM, Verboon-Maciolek MA. Postnatally acquired cytomegalovirus infection in preterm infants: a prospective study on risk factors and cranial ultrasound findings. Arch Dis Child Fetal Neonatal Ed. 2012;97(4):F259–63. Epub 2012/01/17.CrossRefPubMedGoogle Scholar
  2. 2.
    Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988;82(4):527–32. Epub 1988/10/01.PubMedGoogle Scholar
  3. 3.
    Poindexter BB, Feng R, Schmidt B, Aschner JL, Ballard RA, Hamvas A, et al. Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program. Ann Am Thorac Soc. 2015;12(12):1822–30. Epub 2015/09/24.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723–9. Epub 2001/06/13.CrossRefPubMedGoogle Scholar
  5. 5.
    McEvoy CT, Jain L, Schmidt B, Abman S, Bancalari E, Aschner JL. Bronchopulmonary dysplasia: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. Ann Am Thorac Soc. 2014;11(Suppl 3):S146–53. Epub 2014/04/24.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Northway Jr WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276(7):357–68. Epub 1967/02/16.CrossRefPubMedGoogle Scholar
  7. 7.
    Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med. 2007;357(19):1946–55. Epub 2007/11/09.CrossRefPubMedGoogle Scholar
  8. 8.
    Wang H, St Julien KR, Stevenson DK, Hoffmann TJ, Witte JS, Lazzeroni LC, et al. A genome-wide association study (GWAS) for bronchopulmonary dysplasia. Pediatrics. 2013;132(2):290–7. Epub 2013/07/31.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lal CV, Ambalavanan N. Genetic predisposition to bronchopulmonary dysplasia. Semin Perinatol. 2015;39(8):584–91. Epub 2015/10/17.CrossRefPubMedGoogle Scholar
  10. 10.
    Lowe J, Watkins WJ, Edwards MO, Spiller OB, Jacqz-Aigrain E, Kotecha SJ, et al. Association between pulmonary ureaplasma colonization and bronchopulmonary dysplasia in preterm infants: updated systematic review and meta-analysis. Pediatr Infect Dis J. 2014;33(7):697–702. Epub 2014/01/22.CrossRefPubMedGoogle Scholar
  11. 11.
    Higgins RD, Saade G, Polin RA, Grobman WA, Buhimschi IA, Watterberg K, et al. Evaluation and management of women and newborns with a maternal diagnosis of chorioamnionitis: summary of a workshop. Obstet Gynecol. 2016;127(3):426–36. Epub 2016/02/09.CrossRefPubMedGoogle Scholar
  12. 12.
    Kunzmann S, Collins JJ, Kuypers E, Kramer BW. Thrown off balance: the effect of antenatal inflammation on the developing lung and immune system. Am J Obstet Gynecol. 2013;208(6):429–37. Epub 2013/01/15.CrossRefPubMedGoogle Scholar
  13. 13.
    Lee J, Romero R, Xu Y, Kim JS, Topping V, Yoo W, et al. A signature of maternal anti-fetal rejection in spontaneous preterm birth: chronic chorioamnionitis, anti-human leukocyte antigen antibodies, and C4d. PLoS One. 2011;6(2):e16806.Epub 2011/02/18.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371(9606):75–84. Epub 2008/01/08.CrossRefPubMedGoogle Scholar
  15. 15.
    Viscardi RM, Kallapur SG. Role of ureaplasma respiratory tract colonization in bronchopulmonary dysplasia pathogenesis: current concepts and update. Clin Perinatol. 2015;42(4):719–38. Epub 2015/11/26.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Murtha AP, Edwards JM. The role of Mycoplasma and Ureaplasma in adverse pregnancy outcomes. Obstet Gynecol Clin North Am. 2014;41(4):615–27. Epub 2014/12/03.CrossRefPubMedGoogle Scholar
  17. 17.
    Waites KB, Xiao L, Paralanov V, Viscardi RM, Glass JI. Molecular methods for the detection of Mycoplasma and ureaplasma infections in humans: a paper from the 2011 William Beaumont Hospital Symposium on molecular pathology. J Mol Diagn. 2012;14(5):437–50. Epub 2012/07/24.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med. 2000;342(20):1500–7. Epub 2000/05/18.CrossRefPubMedGoogle Scholar
  19. 19.
    Sanchez PJ. Perinatal transmission of Ureaplasma urealyticum: current concepts based on review of the literature. Clin Infect Dis. 1993;17(Suppl 1):S107–11. Epub 1993/08/01.CrossRefPubMedGoogle Scholar
  20. 20.
    Schelonka RL, Katz B, Waites KB, Benjamin Jr DK. Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J. 2005;24(12):1033–9. Epub 2005/12/24.CrossRefPubMedGoogle Scholar
  21. 21.
    Sanchez PJ, Regan JA. Ureaplasma urealyticum colonization and chronic lung disease in low birth weight infants. Pediatr Infect Dis J. 1988;7(8):542–6. Epub 1988/08/01.PubMedGoogle Scholar
  22. 22.
    Zheng X, Teng LJ, Watson HL, Glass JI, Blanchard A, Cassell GH. Small repeating units within the Ureaplasma urealyticum MB antigen gene encode serovar specificity and are associated with antigen size variation. Infect Immun. 1995;63(3):891–8. Epub 1995/03/01.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Sung TJ, Xiao L, Duffy L, Waites KB, Chesko KL, Viscardi RM. Frequency of ureaplasma serovars in respiratory secretions of preterm infants at risk for bronchopulmonary dysplasia. Pediatr Infect Dis J. 2011;30(5):379–83. Epub 2010/11/26.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Robinson JW, Dando SJ, Nitsos I, Newnham J, Polglase GR, Kallapur SG, et al. Ureaplasma parvum serovar 3 multiple banded antigen size variation after chronic intra-amniotic infection/colonization. PLoS One. 2013;8(4):e62746.Epub 2013/05/03.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Okogbule-Wonodi AC, Chesko KL, Famuyide ME, Viscardi RM. Surfactant protein-A enhances ureaplasmacidal activity in vitro. Innate Immun. 2011;17(2):145–51. Epub 2010/03/04.CrossRefPubMedGoogle Scholar
  26. 26.
    Famuyide ME, Hasday JD, Carter HC, Chesko KL, He JR, Viscardi RM. Surfactant protein-A limits Ureaplasma-mediated lung inflammation in a murine pneumonia model. Pediatr Res. 2009;66(2):162–7. Epub 2009/04/25.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Arntzen KJ, Kjollesdal AM, Halgunset J, Vatten L, Austgulen R. TNF, IL-1, IL-6, IL-8 and soluble TNF receptors in relation to chorioamnionitis and premature labor. J Perinat Med. 1998;26(1):17–26. Epub 1998/05/22.CrossRefPubMedGoogle Scholar
  28. 28.
    D’Angio CT, Ambalavanan N, Carlo WA, McDonald SA, Skogstrand K, Hougaard DM, et al. Blood cytokine profiles associated with distinct patterns of bronchopulmonary dysplasia among extremely low birth weight infants. J Pediatr. 2016;174:45–51.e5. Epub 2016/04/28.CrossRefPubMedGoogle Scholar
  29. 29.
    Bry K, Lappalainen U, Hallman M. Intraamniotic interleukin-1 accelerates surfactant protein synthesis in fetal rabbits and improves lung stability after premature birth. J Clin Invest. 1997;99(12):2992–9. Epub 1997/06/15.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics. 1996;97(2):210–5. Epub 1996/02/01.PubMedGoogle Scholar
  31. 31.
    Been JV, Zimmermann LJ. Histological chorioamnionitis and respiratory outcome in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2009;94(3):F218–25. Epub 2009/01/10.CrossRefPubMedGoogle Scholar
  32. 32.
    Morrisey EE, Hogan BL. Preparing for the first breath: genetic and cellular mechanisms in lung development. Dev Cell. 2010;18(1):8–23. Epub 2010/02/16.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Kramer BW, Kallapur S, Newnham J, Jobe AH. Prenatal inflammation and lung development. Semin Fetal Neonatal Med. 2009;14(1):2–7. Epub 2008/10/11.CrossRefPubMedGoogle Scholar
  34. 34.
    Charafeddine L, D’Angio CT, Phelps DL. Atypical chronic lung disease patterns in neonates. Pediatrics. 1999;103(4 Pt 1):759–65. Epub 1999/04/02.CrossRefPubMedGoogle Scholar
  35. 35.
    Kramer BW, Ladenburger A, Kunzmann S, Speer CP, Been JV, van Iwaarden JF, et al. Intravenous lipopolysaccharide-induced pulmonary maturation and structural changes in fetal sheep. Am J Obstet Gynecol. 2009;200(2):195.e1–10. Epub 2008/12/27.Google Scholar
  36. 36.
    Benjamin JT, Carver BJ, Plosa EJ, Yamamoto Y, Miller JD, Liu JH, et al. NF-kappaB activation limits airway branching through inhibition of Sp1-mediated fibroblast growth factor-10 expression. J Immunol. 2010;185(8):4896–903. Epub 2010/09/24.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1(6):a001651. Epub 2010/05/12.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Beers MF, Morrisey EE. The three R’s of lung health and disease: repair, remodeling, and regeneration. J Clin Invest. 2011;121(6):2065–73. Epub 2011/06/03.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Kallapur SG, Bachurski CJ, Le Cras TD, Joshi SN, Ikegami M, Jobe AH. Vascular changes after intra-amniotic endotoxin in preterm lamb lungs. Am J Physiol Lung Cell Mol Physiol. 2004;287(6):L1178–85. Epub 2004/08/24.CrossRefPubMedGoogle Scholar
  40. 40.
    Thomas W, Seidenspinner S, Kramer BW, Kawczynska-Leda N, Chmielnicka-Kopaczyk M, Marx A, et al. Airway concentrations of angiopoietin-1 and endostatin in ventilated extremely premature infants are decreased after funisitis and unbalanced with bronchopulmonary dysplasia/death. Pediatr Res. 2009;65(4):468–73. Epub 2009/01/08.CrossRefPubMedGoogle Scholar
  41. 41.
    Choi CW, Lee J, Oh JY, Lee SH, Lee HJ, Kim BI. Protective effect of chorioamnionitis on the development of bronchopulmonary dysplasia triggered by postnatal systemic inflammation in neonatal rats. Pediatr Res. 2016;79(2):287–94. Epub 2015/11/10.CrossRefPubMedGoogle Scholar
  42. 42.
    Thomas W, Speer CP. Chorioamnionitis is essential in the evolution of bronchopulmonary dysplasia – the case in favour. Paediatr Respir Rev. 2014;15(1):49–52. Epub 2013/10/17.PubMedGoogle Scholar
  43. 43.
    Dessardo NS, Mustac E, Dessardo S, Banac S, Peter B, Finderle A, et al. Chorioamnionitis and chronic lung disease of prematurity: a path analysis of causality. Am J Perinatol. 2012;29(2):133–40. Epub 2011/12/08.CrossRefPubMedGoogle Scholar
  44. 44.
    Been JV, Rours IG, Kornelisse RF, Jonkers F, de Krijger RR, Zimmermann LJ. Chorioamnionitis alters the response to surfactant in preterm infants. J Pediatr. 2010;156(1):10–5.e1. Epub 2009/10/17.CrossRefPubMedGoogle Scholar
  45. 45.
    Balany J, Bhandari V. Understanding the impact of infection, inflammation, and their persistence in the pathogenesis of bronchopulmonary dysplasia. Front Med (Lausanne). 2015;2:90. Epub 2016/01/07.Google Scholar
  46. 46.
    Hillman NH, Polglase GR, Pillow JJ, Saito M, Kallapur SG, Jobe AH. Inflammation and lung maturation from stretch injury in preterm fetal sheep. Am J Physiol Lung Cell Mol Physiol. 2011;300(2):L232–41. Epub 2010/12/07.CrossRefPubMedGoogle Scholar
  47. 47.
    Carvalho CG, Silveira RC, Procianoy RS. Ventilator-induced lung injury in preterm infants. Rev Bras Ter Intensiva. 2013;25(4):319–26. Epub 2014/02/21.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Beresford MW, Shaw NJ. Detectable IL-8 and IL-10 in bronchoalveolar lavage fluid from preterm infants ventilated for respiratory distress syndrome. Pediatr Res. 2002;52(6):973–8. Epub 2002/11/20.CrossRefPubMedGoogle Scholar
  49. 49.
    Thickett DR, Armstrong L, Christie SJ, Millar AB. Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome. Am J Respir Crit Care Med. 2001;164(9):1601–5. Epub 2001/11/24.CrossRefPubMedGoogle Scholar
  50. 50.
    Salaets T, Richter J, Brady P, Jimenez J, Nagatomo T, Deprest J, et al. Transcriptome analysis of the preterm rabbit lung after seven days of hyperoxic exposure. PLoS One. 2015;10(8):e0136569.Epub 2015/09/01.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Weinberger B, Laskin DL, Heck DE, Laskin JD. Oxygen toxicity in premature infants. Toxicol Appl Pharmacol. 2002;181(1):60–7. Epub 2002/05/29.CrossRefPubMedGoogle Scholar
  52. 52.
    Yee M, Chess PR, McGrath-Morrow SA, Wang Z, Gelein R, Zhou R, et al. Neonatal oxygen adversely affects lung function in adult mice without altering surfactant composition or activity. Am J Physiol Lung Cell Mol Physiol. 2009;297(4):L641–9. Epub 2009/07/21.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Kramer BW. Chorioamnionitis - new ideas from experimental models. Neonatology. 2011;99(4):320–5. Epub 2011/06/28.CrossRefPubMedGoogle Scholar
  54. 54.
    Kallapur SG, Jobe AH, Ball MK, Nitsos I, Moss TJ, Hillman NH, et al. Pulmonary and systemic endotoxin tolerance in preterm fetal sheep exposed to chorioamnionitis. J Immunol. 2007;179(12):8491–9. Epub 2007/12/07.CrossRefPubMedGoogle Scholar
  55. 55.
    Kallapur SG, Kramer BW, Knox CL, Berry CA, Collins JJ, Kemp MW, et al. Chronic fetal exposure to Ureaplasma parvum suppresses innate immune responses in sheep. J Immunol. 2011;187(5):2688–95. Epub 2011/07/26.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Kramer BW, Jobe AH. The clever fetus: responding to inflammation to minimize lung injury. Biol Neonate. 2005;88(3):202–7. Epub 2005/10/08.CrossRefPubMedGoogle Scholar
  57. 57.
    Azizia M, Lloyd J, Allen M, Klein N, Peebles D. Immune status in very preterm neonates. Pediatrics. 2012;129(4):e967–74. Epub 2012/03/28.CrossRefPubMedGoogle Scholar
  58. 58.
    Kallapur SG, Nitsos I, Moss TJ, Kramer BW, Newnham JP, Ikegami M, et al. Chronic endotoxin exposure does not cause sustained structural abnormalities in the fetal sheep lungs. Am J Physiol Lung Cell Mol Physiol. 2005;288(5):L966–74. Epub 2005/01/11.CrossRefPubMedGoogle Scholar
  59. 59.
    Shah J, Jefferies AL, Yoon EW, Lee SK, Shah PS. Risk factors and outcomes of late-onset bacterial sepsis in preterm neonates born at < 32 weeks’ gestation. Am J Perinatol. 2015;32(7):675–82. Epub 2014/12/09.PubMedGoogle Scholar
  60. 60.
    Shane AL, Stoll BJ. Neonatal sepsis: progress towards improved outcomes. J Infect. 2014;68(Suppl 1):S24–32. Epub 2013/10/22.CrossRefPubMedGoogle Scholar
  61. 61.
    Kramer BW, Kramer S, Ikegami M, Jobe AH. Injury, inflammation, and remodeling in fetal sheep lung after intra-amniotic endotoxin. Am J Physiol Lung Cell Mol Physiol. 2002;283(2):L452–9. Epub 2002/07/13.CrossRefPubMedGoogle Scholar
  62. 62.
    Adams-Chapman I. Long-term impact of infection on the preterm neonate. Semin Perinatol. 2012;36(6):462–70.CrossRefPubMedGoogle Scholar
  63. 63.
    Alford CA, Stagno S, Pass RF, Britt WJ. Congenital and perinatal cytomegalovirus infections. Rev Infect Dis. 1990;12(Suppl 7):S745–53. Epub 1990/09/01.CrossRefPubMedGoogle Scholar
  64. 64.
    Pryhuber GS. Postnatal infections and immunology affecting chronic lung disease of prematurity. Clin Perinatol. 2015;42(4):697–718. Epub 2015/11/26.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    de Cates CR, Gray J, Roberton NR, Walker J. Acquisition of cytomegalovirus infection by premature neonates. J Infect. 1994;28(1):25–30. Epub 1994/01/01.CrossRefPubMedGoogle Scholar
  66. 66.
    Capretti MG, Lanari M, Lazzarotto T, Gabrielli L, Pignatelli S, Corvaglia L, et al. Very low birth weight infants born to cytomegalovirus-seropositive mothers fed with their mother’s milk: a prospective study. J Pediatr. 2009;154(6):842–8. Epub 2009/02/24.CrossRefPubMedGoogle Scholar
  67. 67.
    Maschmann J, Hamprecht K, Dietz K, Jahn G, Speer CP. Cytomegalovirus infection of extremely low-birth weight infants via breast milk. Clin Infect Dis. 2001;33(12):1998–2003. Epub 2001/11/17.CrossRefPubMedGoogle Scholar
  68. 68.
    Whitley RJ, Brasfield D, Reynolds DW, Stagno S, Tiller RE, Alford CA. Protracted pneumonitis in young infants associated with perinatally acquired cytomegaloviral infection. J Pediatr. 1976;89(1):16–22. Epub 1976/07/01.CrossRefPubMedGoogle Scholar
  69. 69.
    Neuberger P, Hamprecht K, Vochem M, Maschmann J, Speer CP, Jahn G, et al. Case-control study of symptoms and neonatal outcome of human milk-transmitted cytomegalovirus infection in premature infants. J Pediatr. 2006;148(3):326–31. Epub 2006/04/18.CrossRefPubMedGoogle Scholar
  70. 70.
    Bradshaw JH, Moore PP. Perinatal cytomegalovirus infection associated with lung cysts. J Paediatr Child Health. 2003;39(7):563–6. Epub 2003/09/13.CrossRefPubMedGoogle Scholar
  71. 71.
    Koklu E, Karadag A, Tunc T, Altun D, Sarici SU. Congenital cytomegalovirus infection associated with severe lung involvement in a preterm neonate: a causal relationship? Eur J Pediatr. 2009;168(11):1409–12. Epub 2009/02/19.CrossRefPubMedGoogle Scholar
  72. 72.
    Mukhopadhyay S, Meyer SA, Permar SR, Puopolo KM. Symptomatic postnatal cytomegalovirus testing among very low-birth-weight infants: indications and outcomes. Am J Perinatol. 2016; Epub 2016/04/09.Google Scholar
  73. 73.
    Kelly MS, Benjamin DK, Puopolo KM, Laughon MM, Clark RH, Mukhopadhyay S, et al. Postnatal cytomegalovirus infection and the risk for bronchopulmonary dysplasia. JAMA Pediatr. 2015;169(12):e153785.Epub 2015/12/08.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Josephson CD, Caliendo AM, Easley KA, Knezevic A, Shenvi N, Hinkes MT, et al. Blood transfusion and breast milk transmission of cytomegalovirus in very low-birth-weight infants: a prospective cohort study. JAMA Pediatr. 2014;168(11):1054–62. Epub 2014/09/23.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Hayashi S, Kimura H, Oshiro M, Kato Y, Yasuda A, Suzuki C, et al. Transmission of cytomegalovirus via breast milk in extremely premature infants. J Perinatol. 2011;31(6):440–5. Epub 2010/12/18.CrossRefPubMedGoogle Scholar
  76. 76.
    Lombardi G, Garofoli F, Manzoni P, Stronati M. Breast milk-acquired cytomegalovirus infection in very low birth weight infants. J Matern Fetal Neonatal Med. 2012;25(Suppl 3):57–62. Epub 2012/10/04.CrossRefPubMedGoogle Scholar
  77. 77.
    Bennett NJ, Tabarani CM, Bartholoma NM, Wang D, Huang D, Riddell SW, et al. Unrecognized viral respiratory tract infections in premature infants during their birth hospitalization: a prospective surveillance study in two neonatal intensive care units. J Pediatr. 2012;161(5):814–8. Epub 2012/06/15.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Kidszun A, Klein L, Winter J, Schmeh I, Grondahl B, Gehring S, et al. Viral infections in neonates with suspected late-onset bacterial sepsis – a Prospective Cohort Study. Am J Perinatol. 2016; Epub 2016/05/18.Google Scholar
  79. 79.
    Ronchi A, Michelow IC, Chapin KC, Bliss JM, Pugni L, Mosca F, et al. Viral respiratory tract infections in the neonatal intensive care unit: the VIRIoN-I study. J Pediatr. 2014;165(4):690–6. Epub 2014/07/17.CrossRefPubMedGoogle Scholar
  80. 80.
    O’Reilly MA, Marr SH, Yee M, McGrath-Morrow SA, Lawrence BP. Neonatal hyperoxia enhances the inflammatory response in adult mice infected with influenza A virus. Am J Respir Crit Care Med. 2008;177(10) Epub 2008/02/23.:1103–10.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Buczynski BW, Yee M, Martin KC, Lawrence BP, O’Reilly MA. Neonatal hyperoxia alters the host response to influenza A virus infection in adult mice through multiple pathways. Am J Physiol Lung Cell Mol Physiol. 2013;305(4):L282–90. Epub 2013/06/12.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Buczynski BW, Yee M, Paige Lawrence B, O’Reilly MA. Lung development and the host response to influenza A virus are altered by different doses of neonatal oxygen in mice. Am J Physiol Lung Cell Mol Physiol. 2012;302(10):L1078–87. Epub 2012/03/13.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Maduekwe ET, Buczynski BW, Yee M, Rangasamy T, Stevens TP, Lawrence BP, et al. Cumulative neonatal oxygen exposure predicts response of adult mice infected with influenza A virus. Pediatr Pulmonol. 2014; doi: 10.1002/ppul.23063. Epub 2014/05/23.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Lee KK, Hegele RG, Manfreda J, Wooldrage K, Becker AB, Ferguson AC, et al. Relationship of early childhood viral exposures to respiratory symptoms, onset of possible asthma and atopy in high risk children: the Canadian Asthma Primary Prevention Study. Pediatr Pulmonol. 2007;42(3):290–7.CrossRefPubMedGoogle Scholar
  85. 85.
    Jacob SV, Coates AL, Lands LC, MacNeish CF, Riley SP, Hornby L, et al. Long-term pulmonary sequelae of severe bronchopulmonary dysplasia. J Pediatr. 1998;133(2):193–200.CrossRefPubMedGoogle Scholar
  86. 86.
    Greenough A. Long term respiratory outcomes of very premature birth (<32 weeks). Semin Fetal Neonatal Med. 2012;17(2):73–6. Epub 2012/02/04.CrossRefPubMedGoogle Scholar
  87. 87.
    Stein RT, Martinez FD. Respiratory syncytial virus and asthma: still no final answer. Thorax. 2010;65(12):1033–4. Epub 2010/10/28.CrossRefPubMedGoogle Scholar
  88. 88.
    Resch B, Kurath-Koller S, Eibisberger M, Zenz W. Prematurity and the burden of influenza and respiratory syncytial virus disease. World J Pediatr. 2016;12(1):8–18. Epub 2015/11/20.CrossRefPubMedGoogle Scholar
  89. 89.
    Miller EK, Bugna J, Libster R, Shepherd BE, Scalzo PM, Acosta PL, et al. Human rhinoviruses in severe respiratory disease in very low birth weight infants. Pediatrics. 2012;129(1):e60–7. Epub 2011/12/28.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Broughton S, Bhat R, Roberts A, Zuckerman M, Rafferty G, Greenough A. Diminished lung function, RSV infection, and respiratory morbidity in prematurely born infants. Arch Dis Child. 2006;91(1):26–30. Epub 2005/09/29.CrossRefPubMedGoogle Scholar
  91. 91.
    Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999;354(9178):541–5. Epub 1999/09/02.CrossRefPubMedGoogle Scholar
  92. 92.
    Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med. 1995;332(3):133–8. Epub 1995/01/19.CrossRefPubMedGoogle Scholar
  93. 93.
    Darveaux JI, Lemanske Jr RF. Infection-related asthma. J Allergy Clin Immunol Pract. 2014;2(6):658–63. Epub 2014/12/03.CrossRefPubMedGoogle Scholar
  94. 94.
    de Winter JJ, Bont L, Wilbrink B, van der Ent CK, Smit HA, Houben ML. Rhinovirus wheezing illness in infancy is associated with medically attended third year wheezing in low risk infants: results of a healthy birth cohort study. Immun Inflamm Dis. 2015;3(4):398–405. Epub 2016/01/07.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Carbonell-Estrany X, Perez-Yarza EG, Garcia LS, Guzman Cabanas JM, Boria EV, Atienza BB. Long-term burden and respiratory effects of respiratory syncytial virus hospitalization in preterm infants-The SPRING Study. PLoS One. 2015;10(5):e0125422.Epub 2015/05/09.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531–7. Epub 1998/09/17.Google Scholar
  97. 97.
    Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007;151(1):34–42.e1. Epub 2007/06/26.CrossRefPubMedGoogle Scholar
  98. 98.
    Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med. 2013;368(19):1791–9. Epub 2013/05/10.CrossRefPubMedGoogle Scholar
  99. 99.
    Novitsky A, Tuttle D, Locke RG, Saiman L, Mackley A, Paul DA. Prolonged early antibiotic use and bronchopulmonary dysplasia in very low birth weight infants. Am J Perinatol. 2015;32(1):43–8. Epub 2014/05/06.CrossRefPubMedGoogle Scholar
  100. 100.
    Imamura T, Sato M, Go H, Ogasawara K, Kanai Y, Maeda H, et al. The microbiome of the lower respiratory tract in premature infants with and without severe bronchopulmonary dysplasia. Am J Perinatol. 2016; Epub 2016/05/31.Google Scholar
  101. 101.
    Lal CV, Travers C, Aghai ZH, Eipers P, Jilling T, Halloran B, et al. The airway microbiome at birth. Sci Rep. 2016;6:31023. Epub 2016/08/05.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Lohmann P, Luna RA, Hollister EB, Devaraj S, Mistretta TA, Welty SE, et al. The airway microbiome of intubated premature infants: characteristics and changes that predict the development of bronchopulmonary dysplasia. Pediatr Res. 2014;76(3):294–301. Epub 2014/06/19.CrossRefPubMedGoogle Scholar
  103. 103.
    Cadwell K. The virome in host health and disease. Immunity. 2015;42(5):805–13. Epub 2015/05/21.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Ramilo O, Mejias A. Shifting the paradigm: host gene signatures for diagnosis of infectious diseases. Cell Host Microbe. 2009;6(3):199–200. Epub 2009/09/15.CrossRefPubMedGoogle Scholar
  105. 105.
    Heinonen S, Jartti T, Garcia C, Oliva S, Smitherman C, Anguiano E, et al. Rhinovirus detection in symptomatic and asymptomatic children: value of host transcriptome analysis. Am J Respir Crit Care Med. 2016;193(7):772–82. Epub 2015/11/17.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Phillip S. Wozniak
    • 1
    • 2
  • Mohannad Moallem
    • 1
  • Pablo J. Sánchez
    • 1
    • 3
    • 2
    Email author
  1. 1.Department of Pediatrics, Division of NeonatologyNationwide Children’s Hospital – The Ohio State UniversityColumbusUSA
  2. 2.Nationwide Children’s Hospital – The Ohio State University, Center for Perinatal Research, The Research Institute at Nationwide Children’s HospitalColumbusUSA
  3. 3.Pediatric Infectious DiseasesNationwide Children’s Hospital – The Ohio State UniversityColumbusUSA

Personalised recommendations